ClinicalTrials.gg
CompletedNCT04004988Updated Apr 18, 2023Results posted

A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants

A Phase 1 interventional study of Tirzepatide and Prefilled syringe (PFS) in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in Singapore. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-18.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
21 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to compare the amount of tirzepatide that gets into the blood stream and how long it takes the body to get rid of it, when given as a solution formulation via an autoinjector versus a conventional prefilled syringe. The tolerability of tirzepatide will also be evaluated and information about any adverse effects experienced will be collected.

Screening is required within 28 days prior to the start of the study. For each participant, the total duration of the clinical trial will be about 14 weeks, including screening.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males or females of nonchildbearing potential as determined by medical history, physical examination, and other screening procedures
  • Are between the (BMI) of 18.0 and 32.0 kilograms per meter squared (kg/m²), inclusive, at screening
  • Are agreeable to receiving study treatment by injections under the skin

Exclusion criteria

Exclusion Criteria:

  • Have known allergies to tirzepatide or related compounds
  • Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2
  • Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis), elevation in serum amylase or lipase or GI disorder (eg, relevant esophageal reflux or gall bladder disease) or any GI disease which impacts gastric emptying (eg, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by glucagon-like peptide-1 (GLP-1) analogs or dipeptidyl peptidase IV (DPP-IV) inhibitors
  • Have a prior history of malignant disease(s) in the past 5 years prior to screening
  • Smoke more than the equivalent of 10 cigarettes per day
  • Is a known user of drugs of abuse
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Tirzepatide Test

    Participants received single dose of 5 milligram (mg) Tirzepatide by subcutaneous injection (SC) via an autoinjector (AI) in one of two study periods.

    Drug: Tirzepatide · Device: Auto-injector (AI)

  • Experimental
    Tirzepatide Reference

    Participants received single dose of 5mg Tirzepatide by subcutaneous injection (SC) via a prefilled syringe (PFS) in one of two study periods.

    Drug: Tirzepatide · Device: Prefilled syringe (PFS)

Interventions

  • Administered SC

    Also known as: LY3298176

  • DevicePrefilled syringe (PFS)

    PFS used to administer tirzepatide

  • DeviceAuto-injector (AI)

    AI used to administer tirzepatide

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Infinity (AUC0toinf)

    Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide from Time Zero to Infinity (AUC0toinf) was reported.

    Time frame: Predose, 8hours(h), 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h, 336h , 480h, 864h postdose

  2. PK: Maximum Observed Plasma Concentration (Cmax) of Tirzepatide

    PK: Maximum Observed Plasma Concentration (Cmax) of Tirzepatide was reported

    Time frame: Predose, 8hours(h), 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h, 336h , 480h, 864h postdose

07

Results

Posted Apr 18, 2023

Participant flow

Period 1
Participant flow — Period 1
MilestoneSequence ASequence B
Started2423
Received at least one dose of study drug2223
Completed2120
Not completed33
Withdrew: Physician decision20
Withdrew: Withdrawal by subject01
Withdrew: Adverse event12
Period 2
Participant flow — Period 2
MilestoneSequence ASequence B
Started2120
Received at least one dose of study drug2120
Completed2120
Not completed00

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Infinity (AUC0toinf)

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide from Time Zero to Infinity (AUC0toinf) was reported.

Time frame:
Predose, 8hours(h), 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h, 336h , 480h, 864h postdose
Reported as:
Geometric mean · Nanogram*hour per milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Infinity (AUC0toinf)
Nanogram*hour per milliliter (ng*h/mL)5 mg Tirzepatide AI5 mg Tirzepatide PFS
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Infinity (AUC0toinf)101000 ± 18104000 ± 18
PrimaryPK: Maximum Observed Plasma Concentration (Cmax) of Tirzepatide

PK: Maximum Observed Plasma Concentration (Cmax) of Tirzepatide was reported

Time frame:
Predose, 8hours(h), 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h, 336h , 480h, 864h postdose
Reported as:
Geometric mean · Nanogram per Milliliter (ng/mL)
PK: Maximum Observed Plasma Concentration (Cmax) of Tirzepatide
Nanogram per Milliliter (ng/mL)5 mg Tirzepatide AI5 mg Tirzepatide PFS
PK: Maximum Observed Plasma Concentration (Cmax) of Tirzepatide530 ± 25556 ± 22

Adverse events

Collected over Up to 72 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
5 mg Tirzepatide AI0/42 (0%)0/42 (0%)40/42 (95.2%)
5 mg Tirzepatide PFS0/44 (0%)1/44 (2.3%)42/44 (95.5%)
Most frequent serious events
Most frequent serious events
Event5 mg Tirzepatide AI5 mg Tirzepatide PFS
Catheter site phlebitisGeneral disorders0/421/44
Most frequent other events
Showing 10 of 24
Most frequent other events
Event5 mg Tirzepatide AI5 mg Tirzepatide PFS
Abdominal distensionGastrointestinal disorders20/4229/44
Decreased appetiteMetabolism and nutrition disorders24/4222/44
VomitingGastrointestinal disorders14/4216/44
NauseaGastrointestinal disorders14/4212/44
HeadacheNervous system disorders8/4211/44
EructationGastrointestinal disorders5/428/44
Vessel puncture site bruiseGeneral disorders7/422/44
Catheter site bruiseGeneral disorders3/426/44
Catheter site erythemaGeneral disorders4/426/44
DiarrhoeaGastrointestinal disorders4/422/44

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)All Participants
Mean44.6 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female10
Male37
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino0
Not Hispanic or Latino47
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian47
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)All Participants
Singapore47
08

Study locations

1 site
  • Lilly Nus Centre for Clin Pharmacology
    Singapore, 138623, Singapore
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Dec 2019, 3 months.

Results were first posted in Apr 2023, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2019
First posted
Jul 2, 2019
StartActual
Aug 19, 2019
Primary completionActual
Dec 16, 2019
CompletionActual
Dec 16, 2019
Results first posted
Apr 18, 2023
Last update
Apr 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04004988
Responsible party
Sponsor
First posted
Jul 2, 2019
Start date
Aug 19, 2019
Primary completion
Dec 16, 2019
Completion
Dec 16, 2019
Results posted
Apr 18, 2023
Last update
Apr 18, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion